How common are myeloproliferative neoplasms? A systematic review and meta‐analysis

Overview of attention for article published in American Journal of Hematology, March 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 7 news outlets
twitter: 1 X user
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
reddit: 1 Redditor
guideline: 2 clinical guideline sources

Readers on

mendeley: 285 Mendeley

So far, Altmetric has seen 7 news stories from 7 outlets.

Syncona : IOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH

MarketScreener, 08 Dec 2025

Geneva, Switzerland and Amsterdam, The Netherlands and Cambridge, Massachusetts, USA, December 4, 2025 - iOnctura, a clinical-sta…

News story from Finanz Nachrichten on Thursday 04 December 2025

Finanz Nachrichten, 04 Dec 2025

iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH

ADFN, 04 Dec 2025

First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of…

iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new non-clinical data at ASH

Yahoo! Finance USA, 04 Dec 2025

First patient dosed in Phase I/II HEMA-MED clinical trial (NCT06887803) evaluating the tolerability and efficacy profile of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.